X4 Pharmaceuticals (XFOR) Capital Expenditures (2017 - 2025)
X4 Pharmaceuticals (XFOR) reported Capital Expenditures of $500000.0 for Q4 2025, up 1119.51% on a YoY basis from $41000.0 in Q4 2024, and up 1119.51% quarter-over-quarter from $41000.0 in Q4 2024.
X4 Pharmaceuticals (XFOR) Capital Expenditures (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Capital Expenditures for 9 years, with the latest figure at $500000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures rose 1119.51% year-over-year to $500000.0; the trailing twelve-month figure through Dec 2025 stood at $500000.0 (up 53.37% YoY), and the FY2025 full-year result was $500000.0, up 53.37% from the prior year.
- Capital Expenditures for Q4 2025 stood at $500000.0, up from $41000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $500000.0 in Q4 2025, with the low at -$25000.0 in Q4 2023.
- Historically, Capital Expenditures has averaged $90823.5 across 5 years, with a median of $34000.0 in 2022.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 173.53% — and 2024, when it soared 1588.89%.
- X4 Pharmaceuticals' Capital Expenditures stood at $13000.0 in 2021, then soared by 161.54% to $34000.0 in 2022, then plunged by 173.53% to -$25000.0 in 2023, then soared by 264.0% to $41000.0 in 2024, then surged by 1119.51% to $500000.0 in 2025.
- The last three Capital Expenditures figures came in at $500000.0 (Q4 2025), $41000.0 (Q4 2024), and $92000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -63,220.27 |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 500,000.00 |
| Dec 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Jun 30, 2023 | -9,000.00 |
| Jun 30, 2023 | -9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Dec 31, 2022 | 34,000.00 |